Scinai Immunotherapeutics (SCNI) earnings
Scinai Immunotherapeutics earnings: last reported Wed, 26 Aug 2026, for the quarter ended Jun 2026.
Scinai Immunotherapeutics earnings callsScinai Immunotherapeutics earnings calls (SCNI)
Scinai Immunotherapeutics H1 FY26 — CDMO Expansion and Execution Focus
What went well
- H1 FY26 revenue increased to $949,000 from $773,000 in H1 FY25.
- Reported net income of $1.57 million for H1 FY26, primarily due to a $6.4 million bargain purchase gain from the Recipharm acquisition.
- Committed customer orders totaled $3.1 million as of August 16, with activity distributed almost equally between Jerusalem and Yavne CDMO sites.
What to watch
- Reported a gross loss of $2.37 million and an operating loss of $4.6 million for H1 FY26 due to the expanded CDMO footprint's fixed costs before full utilization.
- Cash and restricted cash stood at $2.85 million as of June 30, 2026, with the company acknowledging the need for additional capital.
Performance −88.2% 1Y
1Y: $12 on 29 Sept 2025 → $1.42. High $16.3 (8 Oct 2025), low $1.41 (29 Sept 2026).
Quarterly results
| Line item | Q1 FY22 | Q2 FY22 | Q1 FY23 | Q2 FY23 |
|---|---|---|---|---|
| EBITDA | -3 | -3 | -3 | -3 |
| Net profit | -2 | -3 | -4 | -4 |
How to read this
US$ million, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Balance sheet
| Year ending | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Reserves | -$110.04M | -$115.83M | -$122.33M | -$117.54M | -$125.85M |
| Total liabilities | $31.05M | $28.83M | $22.04M | $3.47M | $3.52M |
| Fixed assets | $12.39M | $11.24M | $10.82M | $9.19M | $7.79M |
| Total assets | $32.04M | $27.07M | $17.47M | $13.45M | $11.63M |
How to read this
As filed on each reporting date, including interim balance sheets. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Insider filings
2 filings, all on Jun 16, 2026.
Open market
decisions to buy or sellNobody bought or sold SCNI on the open market in this window. The filings below are 2 awards.
Compensation
not trading decisions- 2
- Award — granted as compensation
Latest filings (2)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Reichman Amir Chief Executive Officer | Award | 400,000,000 | $0 |
| Jun 16, 2026 | GERMAIN MARK Director | Award | 120,000,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.